Get the Stockscreener App
3.25
1.56%
0.05
Elutia Inc stock is traded at $3.25, with a volume of 39,408.
It is up +1.56% in the last 24 hours and down -32.85% over the past month.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
See More
Previous Close:
$3.20
Open:
$3.4499
24h Volume:
39,408
Relative Volume:
0.95
Market Cap:
$112.33M
Revenue:
$24.99M
Net Income/Loss:
$-65.24M
P/E Ratio:
-1.1364
EPS:
-2.86
Net Cash Flow:
$-21.27M
1W Performance:
+11.30%
1M Performance:
-32.85%
6M Performance:
-18.75%
1Y Performance:
-18.55%
1-Day Range:
$3.15
$3.4499
1-Week Range:
$2.96
$3.4499
52-Week Range:
$2.28
$5.24
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
3.25 | 112.33M | 24.99M | -65.24M | -21.27M | -2.86 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-02-20 | Initiated | Cowen | Outperform |
| Nov-02-20 | Initiated | Piper Sandler | Overweight |
| Nov-02-20 | Initiated | Truist | Buy |
Elutia Inc Stock (ELUT) Latest News
Elutia announces full U.S. commercial launch of EluPro - Yahoo Finance
Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand - The Manila Times
Elutia Inc. Announces Full Launch of EluPro? Following Strong Initial Demand - Marketscreener.com
Elutia Inc. (NASDAQ:ELUT) Stock Position Lifted by Geode Capital Management LLC - Defense World
Elutia secures deal to supply antibiotic bioenvelope By Investing.com - Investing.com Australia
Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners - The Manila Times
Elutia secures deal to supply antibiotic bioenvelope - Investing.com
Elutia's Revolutionary EluPro Antibiotic Device Gains Access to 993 Healthcare Facilities - StockTitan
Elutia Inc. (NASDAQ:ELUT) Not Doing Enough For Some Investors As Its Shares Slump 27% - Simply Wall St
Are Medical Stocks Lagging ELUTIA INC (ELUT) This Year? - Yahoo Finance
Elutia (NASDAQ:ELUT) Trading 1.9% HigherHere's Why - MarketBeat
Elutia (NASDAQ:ELUT) Trading Up 1.9% – Here’s Why - Defense World
Elutia awarded cardian rhythm management devices agreement with Premier - TipRanks
Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc. - The Manila Times
ELUTElutia Inc. Latest Stock News & Market Updates - StockTitan
Elutia Inc. (NASDAQ:ELUT) Held Back By Insufficient Growth Even After Shares Climb 26% - Simply Wall St
Elutia Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Elutia Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cantor Fitzgerald Reaffirms Overweight Rating for Elutia (NASDAQ:ELUT) - Defense World
Elutia's (ELUT) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Elutia Inc (ELUT) Q3 2024 Earnings Call Highlights: Strategic Gr - GuruFocus.com
Elutia Inc (ELUT) Q3 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges By GuruFocus - Investing.com Canada
Elutia Inc. (ELUT) Quarterly 10-Q Report - Quartzy
Elutia Inc. Reports Strong Q3 Results, Prepares for Major Product Launch - TipRanks
Elutia Inc (ELUT) Q3 2024 Earnings: EPS of $0.03 Beats Estimates, Revenue of $5.92M Misses Expectations - GuruFocus.com
Elutia earnings beat by $0.11, revenue fell short of estimates - Investing.com UK
Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025 - The Manila Times
Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Manila Times
What To Expect From Elutia Inc (ELUT) Q3 2024 Earnings - GuruFocus.com
Elutia (ELUT) to Release Earnings on Thursday - Defense World
Elutia (ELUT) Set to Announce Earnings on Thursday - MarketBeat
Short Interest in Elutia Inc. (NASDAQ:ELUT) Rises By 7.4% - MarketBeat
Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024 - The Manila Times
Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30 - The Manila Times
Individual investors among Elutia Inc.'s (NASDAQ:ELUT) largest stockholders and were hit after last week's 10% price drop - Simply Wall St
Contaminated donor tissue gave Georgia patient tuberculosis, lawsuit says - The Atlanta Journal Constitution
SILVERARC CAPITAL MANAGEMENT, LLC Acquires Shares in Elutia Inc - GuruFocus.com
Preclinical Data Show Efficacy Of Elutia's Antibiotic-Eluting BioEnvelope - MPO-mag
Preclinical Data Show Efficacy of Elutia’s Antibiotic-Eluting BioEnvelope - MPO-mag
Elutia (NASDAQ:ELUT) vs. Curis (NASDAQ:CRIS) Head to Head Comparison - Defense World
Nantahala Capital Management LLC Grows Stock Position in Elutia Inc. (NASDAQ:ELUT) - Defense World
Nantahala Capital Management LLC Purchases 145,697 Shares of Elutia Inc. (NASDAQ:ELUT) - MarketBeat
Short Interest in Elutia Inc. (NASDAQ:ELUT) Declines By 30.1% - MarketBeat
Elutia Inc. (NASDAQ:ELUT) Sees Large Decrease in Short Interest - Defense World
Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices - StockTitan
Short Interest in Elutia Inc. (NASDAQ:ELUT) Decreases By 10.9% - MarketBeat
Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators - HMP Global Learning Network
Elutia announces first patient implant of EluPro, the world’s first drug-eluting bioenvelope for cardiac pacemakers and neurostimulators - Cardiovascular Business
AIGH Capital Management LLC Increases Position in Elutia Inc. (NASDAQ:ELUT) - MarketBeat
Cantor Fitzgerald Reiterates “Overweight” Rating for Elutia (NASDAQ:ELUT) - Defense World
Elutia Celebrates First Year - ForexTV.com
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):